ClinicalTrials.gg
CompletedNCT06674915Updated Jan 30, 2026

Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment

A Phase 1 interventional study of HRS-5965 capsules in Complement Mediated Primary or Secondary Glomerular Diseases, sponsored by Chengdu Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Chengdu Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The study is being conducted to compare the pharmacokinetics, safety, and pharmacodynamics of HRS-5965 in subjects with mild to moderate hepatic impairment and normal hepatic function.

02

Conditions studied

  • Complement Mediated Primary or Secondary Glomerular Diseases
03

In context

Lead sponsor

Chengdu Suncadia Medicine Co., Ltd. is the lead sponsor of 24 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand the study procedures and methods, participate voluntarily and be able to complete the study according to the protocol requirements, and sign the form (ICF) in writing;
  2. Aged 18-70 years old on the date of signing the ICF (including the threshold), both male and female;
  3. At the time of screening, male subjects weighing no less than 50 kg and female subjects weighing no less than 45 kg; (BMI): 18\~32 kg/m2 (including the threshold);
  4. Subjects with must agree to have no plans for childbearing and voluntarily use highly effective with their partner from the time of signing the ICF until 1 month after administration of the test drug, and to avoid sperm/egg donation. Female subjects of childbearing potential must have a negative serum pregnancy test at both screening and baseline and not be breastfeeding.

    For subjects with hepatic impairment, the following inclusion criteria must also be met:

  5. Not on medication within 4 weeks prior to screening, or have at least 4 weeks of stable medication for hepatic impairment and/or other co-morbidities requiring long-term treatment;
  6. classification of Class A or B.

    For subjects with normal hepatic function, the following inclusion criteria must also be met:

  7. The demographic means of subjects in the normal liver function group (Group C) at screening must meet the following matching criteria:

    1. Weight matched to the hepatic impairment group (Group A + Group B) with a mean value ± 10 kg;
    2. Age-matched to the hepatic impairment group (Group A + Group B), mean ± 10 years;
    3. Sex-matched to liver impairment group (Group A + Group B), mean value ± 1 case;
  8. Normal or abnormal physical examination, 12-, vital signs, chest frontal and lateral radiographs/CT, abdominal ultrasound, and laboratory tests (blood routine, blood biochemistry, urine routine, coagulation function, etc.) in the screening and baseline periods were not .

Exclusion criteria

Exclusion Criteria:

  1. Allergic to two or more allergens, or in the judgment of the investigator, may be allergic to the study drug or its components;
  2. Disease or medical condition that, in the judgment of the investigator, may interfere with the absorption, distribution, metabolism, and excretion of the drug or that may reduce compliance;
  3. Prior history of meningococcal infection or a first-degree relative with a history of meningococcal infection;
  4. Existing or suspected infection (at the investigator's discretion) within 2 weeks prior to screening, or fever;
  5. Severe trauma or undergone surgery within 8 weeks prior to screening, or plan to undergo surgery during the trial period;
  6. Participated in a clinical trial of any other drug or medical device within 3 months prior to screening or plan to do so during the study period, or still within 5 half-lives of the drug prior to screening (whichever is longer);
  7. Smoked an average of more than 5 cigarettes per day in the 4 weeks, or consumed an average of more than 15 g of alcohol in a day in the 4 weeks prior to screening (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine, or 50 mL of low-potency liquor), or a positive breath alcohol test at baseline;
  8. History of drug or substance abuse; or a positive urine drug test at screening;
  9. Donated or lost ≥ 400 mL of blood within 8 weeks, or received a blood transfusion within 12 weeks prior to screening;
  10. Malignant tumor, or history of a malignant tumor within 5 years prior to screening (except for primary hepatocellular carcinoma treated with radical surgery without recurrence within 2 years, non-melanoma of the skin for which treatment has been administered without signs of recurrence, and resected cervical intraepithelial neoplasia);
  11. Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg at screening;
  12. (males) > 450 ms and a QTcF (females) > 470 ms at screening, or other 12- abnormalities judged by the investigator to be or unsuitable for participation;
  13. (eGFR) \< 75 mL/min/1.73m2 calculated using the Chronic Kidney Disease Epidemiology Collaborative Study Group (CKD-EPI) formula;
  14. Difficulty in swallowing, collecting blood intravenously, or physically unable to tolerate blood collection, or not expected to complete the entire trial follow-up;
  15. Vaccinated within 2 weeks prior to dosing or plan to receive the vaccine during the study and within 1 month after dosing;
  16. Pre-existing recurrent oral ulcers;
  17. Any physical or psychological disease or condition that, in the judgment of the investigator, is likely to increase the risk of the trial, interfere with compliance with the protocol and ability to complete the trial.

    Additional exclusion criteria for subjects with hepatic impairment (excluded if 1 of these criteria is met):

  18. History of liver transplantation;
  19. Liver failure, or cirrhosis with combination of hepatic encephalopathy, hepatocellular carcinoma, ruptured variceal hemorrhage of the esophagogastric fundus vein, and other complications that, in the judgment of the investigator, make the subject unsuitable for participation in the study;
  20. History of any serious disease other than the primary disease of the liver itself, or a history of and/or abnormal clinically significant clinical laboratory tests that, in the opinion of the investigator, may affect the results of the test, including, but not limited to, a history of circulatory, endocrine, neurological, gastrointestinal, urologic, or hematologic, immunologic, psychiatric, and metabolic disorders;
  21. Positive (HIV) antigen/antibody screen; if syphilis spirochete antibody is positive, additional tolulized red unheated serum test (TRUST) is required, and exclusion is required if TRUST is positive at the same time; if Surface Antigen (HBsAg) is positive, additional Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Quantitative Test is required, and if Virus If hepatitis C virus (HCV) antibody (Anti-HCV) is positive, additional quantitative hepatitis C virus (HCV) ribonucleic acid (RNA) testing is required, and exclusion will be determined by the investigator based on the quantitative results;
  22. Alpha-fetoprotein > 20 ng/mL; (Hb) ≤ 70 g/L; (ALT) or mentholatum aminotransferase (AST) ≥ 5 times the (ULN);
  23. On systemic hormones (except subjects on stable use of ≤ 5 mg/day of prednisone or equivalent doses of ) or other agents within 4 weeks prior to screening, or more than 4 weeks from their last immunosuppressive therapy at screening but are still within the drug's efficacy period (as assessed by the investigator);
  24. On herbal medications within 4 weeks prior to screening;
  25. On albumin within 14 days prior to screening.

    Additional exclusion criteria for subjects with normal hepatic function (excluded if 1 of these criteria is met):

  26. Pre-existing serious primary diseases of vital organs, including but not limited to gastrointestinal, respiratory, renal, hepatic, neurological, hematological, endocrine, oncological, immunological, psychiatric, or cardiovascular diseases;
  27. Positive for any of the HBsAg, Anti-HCV, HIV antigen/antibody, or syphilis spirochete antibody tests;
  28. On any medication (including prescription drugs, over-the-counter medications, herbal medicines, proprietary Chinese medicines and dietary supplements, etc.) within 4 weeks prior to screening; or within 5 half-lives of the medication at the time of screening (whichever is longer).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment group A

    Subjects with mild hepatic impairment.

    Drug: HRS-5965 capsules

  • Experimental
    Treatment group B

    Subjects with moderate hepatic impairment.

    Drug: HRS-5965 capsules

  • Experimental
    Treatment group C

    Subjects with normal hepatic function.

    Drug: HRS-5965 capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    The maximum plasma concentration.

    Time frame: Post-dose at day 1 to day 9.

  2. AUClast

    Area under the concentration curve from time 0 to the last quantifiable concentration.

    Time frame: Post-dose at day 1 to day 9.

  3. AUCinf

    Area under the concentration curve from time 0 to extrapolated infinite time.

    Time frame: Post-dose at day 1 to day 9.

Secondary outcomes

  1. Tmax

    Time to maximum plasma concentration.

    Time frame: Post-dose at day 1 to day 9.

  2. t1/2

    Terminal half-life.

    Time frame: Post-dose at day 1 to day 9.

  3. CL/F

    Apparent clearance.

    Time frame: Post-dose at day 1 to day 9.

  4. Vz/F

    Apparent volume of distribution.

    Time frame: Post-dose at day 1 to day 9.

  5. Incidence and severity of adverse events

    Time frame: Screening period up to day 9.

  6. Change from baseline of alternative pathway activity

    Time frame: Post-dose at day 1.

07

Study locations

1 site
  • The First Affiliated Hospital of Suzhou University
    Suzhou, Jiangsu 215008, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2024 to primary completion in Jan 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 5, 2024
StartActual
Nov 26, 2024
Primary completionActual
Jan 16, 2026
CompletionActual
Jan 16, 2026
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06674915
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Nov 26, 2024
Primary completion
Jan 16, 2026
Completion
Jan 16, 2026
Last update
Jan 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5965

Start the discussion